Key Players and Competitive Dynamics in the Lung Cancer Diagnostic and Screening Market

The lung cancer diagnostic and screening sector is set to experience significant expansion over the coming years, driven by advancements in technology and increased awareness about early detection. With a growing emphasis on better screening methods and diagnostic tools, the market is positioning itself for robust growth through 2030. Here, we explore the projected market size, key players, emerging trends, and industry segmentation shaping the future of this critical healthcare field.

Strong Growth Forecast for the Lung Cancer Diagnostic and Screening Market
The lung cancer diagnostic and screening market is projected to reach $4.04 billion by 2030, expanding at a healthy compound annual growth rate (CAGR) of 9.6%. This anticipated growth stems from several important factors, including the broadening reach of national lung cancer screening programs, a rising preference for low-dose CT screening techniques, and increasing demand for biomarker and blood-based tests. Additionally, growing investments in oncology diagnostics and better access to diagnostic imaging centers are playing a major role in propelling the market forward. Key trends expected to influence market dynamics include the wider introduction of early lung cancer screening initiatives, enhanced use of advanced imaging and biomarker diagnostics, increased focus on screening high-risk populations, expansion of non-invasive diagnostic methods, and the adoption of multimodal diagnostic pathways.

Download a free report of the lung cancer diagnostic and screening market report:
https://www.thebusinessresearchcompany.com/report/lung-cancer-diagnostic-and-screening-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Significant Players Leading the Lung Cancer Diagnostic and Screening Industry
The competitive landscape of the lung cancer diagnostic and screening market features several leading organizations, such as Thermo Fisher Scientific Inc., Abbott Laboratories Inc., Danaher Corporation, Siemens Healthcare GmbH, FUJIFILM Corporation, Koninklijke Philips N.V., GE Healthcare Bio Sciences AB, Quest Diagnostics Incorporated, Agilent Technologies Inc., Illumina Inc., Qiagen Inc., Myriad Genetic Laboratories Inc., NeoGenomics Laboratories Inc., Canon Medical Systems Corporation, Oncimmune Holdings Plc, Riverain Technologies LLC, VisionGate, Foundation Medicine Inc., Biodesix, OncoCyte, and Broncus Medical Inc.

Innovative Collaborations Expanding Lung Cancer Detection Capabilities
In a notable development, Johnson & Johnson MedTech, the medical technology arm of Johnson & Johnson Private Limited, joined forces with the India-based AI healthcare firm Qure.ai in May 2025. Their partnership focuses on enhancing early lung cancer detection across India by deploying AI-powered screening solutions. Qure.ai's advanced imaging technology will be implemented across a network of hospitals to identify lung cancer nodules earlier, thereby improving treatment outcomes and patient prognosis. Qure.ai specializes in artificial intelligence applications for radiology and medical imaging, making this collaboration a significant step toward integrating AI in lung cancer diagnostics.

View the full lung cancer diagnostic and screening market report:
https://www.thebusinessresearchcompany.com/report/lung-cancer-diagnostic-and-screening-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Emerging Trends in Lung Cancer Diagnostics Highlight the Role of AI
Industry players in the lung cancer diagnostic field are increasingly prioritizing the development of cutting-edge technologies, particularly those powered by artificial intelligence (AI). AI-driven solutions are designed to improve screening accuracy, enable continuous monitoring, and deliver real-time feedback for better patient management. For example, in July 2024, Neurabody S.A., a health tech company based in Luxembourg, introduced Posture AI-a machine learning-based tool aimed at predicting posture trends and providing tailored interventions. Although primarily focused on posture correction, the rise of AI-driven health technologies like this reflects a wider industry trend toward personalized, proactive healthcare solutions. These advancements offer promising potential for lung cancer diagnostics as well, by enabling earlier detection and more precise assessments.

Comprehensive Segmentation of the Lung Cancer Diagnostic and Screening Market
This market is broadly segmented by product, test type, cancer type, and end user. The product categories include instruments, and consumables and accessories. Test types cover biomarker tests, imaging tests, biopsies, blood tests, and other diagnostic methods. Cancer classification is divided into non-small cell lung cancer and small cell lung cancer. Key end users span hospitals, independent diagnostic laboratories, diagnostic imaging centers, cancer research institutes, and other healthcare facilities. Further breakdown of instruments includes imaging devices, biopsy devices, and bronchoscopy systems, while consumables include biopsy needles, reagents and assays, imaging contrast agents, and sample collection kits.

By examining these various segments and the growing influence of advanced technologies, the lung cancer diagnostic and screening market is well placed to improve early detection and treatment outcomes globally.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.